Implementing the Latest Evidence for the Diagnosis, Treatment, and Management of Idiopathic Pulmonary Fibrosis (IPF) Webcast Series
Part II of III
: Evidence-based Guidelines for the Diagnosis of Patients with IPF

Release date: March 29, 2016
Expiration date: March 29, 2017
Expected time to completion: 0.50 hour


Steven D. Nathan, MD
Medical Director
Lung Transplant Program
Advanced Lung Disease Program
Inova Pulmonary Hypertension Program
Inova Fairfax Hospital
Fairfax, Virginia

Program Overview

Idiopathic pulmonary fibrosis (IPF) is a devastating fibrotic disorder with a 3-year median survival rate and a variable and unpredictable clinical course. IPF usually occurs in predominantly middle-aged and older adults and is a chronic disease defined by the histopathologic pattern of usual interstitial pneumonia occurring in the absence of an identifiable cause of lung injury. Recent estimates indicate that approximately 90,000 to 190,000 people in the United States suffer from IPF.

The latest IPF treatment guidelines do not make recommendations for any specific pharmacologic therapies and, in fact, make recommendations against the use of historically-used treatments. There has been an unmet need for therapies to prevent the progression of fibrosis in IPF and only recently two new pharmacological agents, nintedanib and pirfenidone, have received US Food and Drug Administration approval for IPF. In addition, rapid advances continue to be made to enable clinically meaningful outcomes in patients with IPF, especially in those with other comorbidities. This series will provide important updates on IPF care for healthcare providers across the patient care spectrum.

Target Audience

This educational initiative has been designed for pulmonologists, internal medicine physicians, and physicians in training involved in the care of patients with IPF.

Learning Objective

Upon completion of this educational activity, participants should be able to:

  • Review the latest evidence-based guidelines for the diagnosis of patients with IPF

Directions to Learner

There are no fees for participating and receiving CME credit for this activity. During the period March 29, 2016 through March 29, 2017, participants must:

  • Read the learning objective and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest by recording the best answer to each question in the answer key on the evaluation form
  • Complete the evaluation form

A statement of credit will be issued upon receipt of a completed activity evaluation form and a completed posttest with a score of 100%. Your statement of credit will be sent to you within 4 weeks.



Accreditation Statement

Integrity Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation

Integrity Continuing Education designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Integrity Continuing Education, Inc. requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflicts of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Steven D. Nathan, MD

  • Consultant: Boehringer Ingelheim, Genentech, Gilead Sciences
  • Speaker: Boehringer Ingelheim, Genentech, Gilead Sciences
  • Research: Boehringer Ingelheim, Genentech, Gilead Sciences

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc., Boehringer Ingelheim, and Genentech do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of Integrity Continuing Education, Inc., Boehringer Ingelheim, and Genentech. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Privacy Policy

When you participate in an online educational activity sponsored by Integrity CE, you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and...(continued)

Minimum System Requirements

Windows XP, Windows 2000, Windows Vista, and Windows 7 Intel Pentium 4, 2.33 + GHz (or equivalent)
Adobe® Flash® Player 10
For optimal performance, the use of Internet Explorer is not recommended.

Mac OS X v10.4 or later
1.8GHz or faster (or equivalent)
Intel Core Duo 1.33GHz or faster (or equivalent)
Adobe® Flash® Player 10

Click here for more information on minimum system requirements.


The information provided at this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.

begin pretest


For optimal performance, the use of Internet Explorer is not recommended.


Sponsored by Integrity Continuing Education, Inc. 
Supported by an educational grants from Boehringer Ingelheim and Genentech.